

ELCC 2022 INDUSTRY SATELLITE SYMPOSIUM

CNS disease management in EGFRm NSCLC

THURSDAY 31 MARCH 2022 | 13:30–15:00 (CEST)

SOUTH HALL 2, PRAGUE CONGRESS CENTRE,
PRAGUE, CZECH REPUBLIC

Welcome and introduction

David Planchard (Chair)

Current management of CNS disease in EGFRm NSCLC: medical oncology perspective

Åslaug Helland

Current management of CNS disease in EGFRm NSCLC: radiation oncology perspective

Stephanie Combs

Addressing CNS relapse risk in early-stage EGFRm NSCLC

Simon Ekman

The future of CNS disease management in EGFRm NSCLC: panel discussion

All faculty

Live audience Q&A

All faculty

Meeting close

David Planchard (Chair)



David Planchard

Gustave Roussy,
France



Åslaug Helland

Oslo University Hospital,
Norway



Stephanie Combs

Technical University
of Munich, Germany



Simon Ekman

Karolinska University
Hospital, Sweden

AstraZeneca's Commitment to Sustainability



\$19 million
invested in
environmental efficiency
projects in 2020
(NRRGG fund)



CPD A Lists
One of three companies
worldwide to achieve
double A listing for
Climate Change and
Water Security for five
consecutive years



89% of our power
is sourced or
generated from
renewable sources



100% of API
(Active Pharmaceutical
Ingredient) discharges
from AstraZeneca sites
were assessed as safe



20% reduction
in our water use
since 2015



**100% of our
vehicles**
will be electric
by 2025



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website

This is a promotional symposium, funded and organised by AstraZeneca

VPM ID: CZ-2977 | Date of preparation: February 2022

AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK

AstraZeneca